- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04717466
Brain Changes in Psoriasis After Secukinumab Treatment
March 18, 2024 updated by: Gil Yosipovitch, University of Miami
Brain Morphological Changes Accompanied by Effective Biologic Treatments for Psoriasis and Their Associations With the Improvement of Well-being, Itch, and Pain
The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hideki Mochizuki, PhD
- Phone Number: 305-243-1648
- Email: hxm414@med.miami.edu
Study Contact Backup
- Name: Leigh Nattkemper, PhD
- Phone Number: 305-588-9734
- Email: Lxn202@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami
-
Principal Investigator:
- Gil Yosipovitch, MD
-
Contact:
- Hideki Mochizuki, PhD
- Phone Number: 305-243-1648
- Email: hxm414@med.miami.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion:
- Between 18 and 65 years of age.
- Psoriasis patients (with/without psoriatic arthritis): Psoriasis Area (BSA) is more than 5%.
- Psoriasis patients must have had a TB test in the past 8 months (if a patient has not had one, the study will provide one).
- Healthy subjects: in general, good health without history of neurological and psychiatric diseases. No chronic itch, pain, skin or systemic conditions currently or in the past.
- Women of child bearing potential will be administered a pregnancy test to verify that they are not pregnant.
- MRI Compatibility: No major contraindication for MRI (pacemaker, vascular stents, metallic ear tubes, and absence of metal implants or braces) as assessed by MRI technologist using site approved screening form.
- Participants have to be able to speak and read English fluently.
- Participants must have signed a written informed consent before being enrolled in the study
Exclusion:
- Individuals under 18 or over 65 years of age.
- Inability to complete the required measures.
- Participants who use antihistamine drugs for itch relief
- Suffering from any disease state or physical condition, which would increase their health risk by study participation.
- Patients with chronic infectious diseases (e.g., mycobacterial and fungal infections and chronic tuberculosis) or inflammatory bowel disease.
- Patients without a negative TB test in the past 12 months.
- Hypersensitivity or anaphylaxis to biologics
- Patients with treatment of biologics should not receive live vaccines. Thus, age appropriate immunizations according to current immunization guidelines must be completed before the experiment.
- Patients with primary immunodeficient lacking IL-17, patients with autoantibodies against IL-17
- Currently enrolled in any investigational study in which the subject is receiving any type of drug, biological, or non-drug therapy.
- Recent initiation (within last 3 months) or change in dose of centrally acting agents such as antidepressants, neuroleptics or neuropathic medications.
- Patients who were previously treated with drugs targeting IL-17
- Patients who have used biologics in the past in the past 8 weeks or Otezla in the past 4 weeks.
- Patients who use centrally acting agents only when they need. The purpose is to avoid a risk of acute effect of these agents on brain activity.
- Current treatment with opioid analgesics.
- Uncontrolled thyroid disease.
- Use of illicit drugs or history of opiate addiction.
- Diagnosis of a major psychiatric disorder such as schizophrenia, major depression or bipolar disorder that is active currently.
- Morbid obesity
- Weight: 250 lb or more
- Any known diseases or disorders that may affect conducting the experiments (e.g., intracranial pathology, claustrophobia, severe respiratory or cardiovascular problems, active fibromyalgia) or diseases that have potential risks of infections (e.g., HIV, Hepatitis C, etc).
- Inability to speak and read English.
- Pregnant.
- Incarcerated.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Psoriasis Group
Psoriasis participants will be given Secukinumab for a total of 4 months.
This is a 300mg subcutaneous injection that will occur at weeks 0, 1, 2, 3, 4, 8, and 12.
|
300mg subcutaneous injection
|
No Intervention: Healthy Group
Healthy participants will not receive any intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gray matter density
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Changes in brain anatomy for psoriasis participants will be reported as the change in gray matter density as measured by Voxel Based Morphometry (VBM) analysis of Magnetic Resonance Imaging (MRI) scans
|
Baseline, Up to Week 4 (Visit 3)
|
Change in brain activity
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Changes in brain activity in psoriasis participants will be measured using Arterial Spin Labeling (ASL) MRI
|
Baseline, Up to Week 4 (Visit 3)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in itch score as measured by the NRS
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Itch will be measured using the Numerical Rating Scaling (NRS) ranging from 0 (no itch) to 10 (the worst itch imaginable).
|
Baseline, Up to Week 4 (Visit 3)
|
Change in pain score as measured by the NRS
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Pain will be measured using a Numerical Rating Scaling (NRS) ranging from 0 (no pain) to 10 (the worst pain imaginable).
|
Baseline, Up to Week 4 (Visit 3)
|
Change in PASI scores
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Severity of psoriasis will be measured using the Psoriasis Area and Severity Index (PASI), ranging from 0 to 100, with a higher score indicating more severe psoriasis.
|
Baseline, Up to Week 4 (Visit 3)
|
Change in participant well-being as measured by WHO-5
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Well-being will be measured using the 5-item World Health Organization Well-Being Index (WHO-5), ranging from 0 to 25, with a higher score indicating better well-being.
|
Baseline, Up to Week 4 (Visit 3)
|
Change in quality of sleep as measured by PSQI scores
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Quality of sleep will be measured using the Pittsburgh Sleep Quality Index (PSQI), ranging from 0 to 49, with a higher score indicating lower sleep quality.
|
Baseline, Up to Week 4 (Visit 3)
|
Change in physical activity as measured by 7D-PAR
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Physical activity will be measured using the 7-days physical activity recall (7D-PAR), ranging from 0 to 27, with a higher score indicating more physical activity.
|
Baseline, Up to Week 4 (Visit 3)
|
Changes in stress in daily life as measured by PSQ
Time Frame: Baseline, Up to Week 4 (Visit 3)
|
Stress in daily life in psoriasis participants will be measured using the Perceived Stress Questionnaire (PSQ), ranging from 0 to 1, with a higher score indicating more stress.
|
Baseline, Up to Week 4 (Visit 3)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Gil Yosipovitch, MD, University of Miami
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 29, 2021
Primary Completion (Estimated)
August 31, 2024
Study Completion (Estimated)
August 31, 2024
Study Registration Dates
First Submitted
January 15, 2021
First Submitted That Met QC Criteria
January 15, 2021
First Posted (Actual)
January 22, 2021
Study Record Updates
Last Update Posted (Actual)
March 20, 2024
Last Update Submitted That Met QC Criteria
March 18, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20200857
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Secukinumab
-
Novartis PharmaceuticalsCompletedPsoriatic Arthritis | Axial SpondyloarthritisSpain
-
Novartis PharmaceuticalsCompletedPsoriasisUnited States
-
Saakshi KhattriCompleted
-
Novartis PharmaceuticalsRecruiting
-
Technical University of MunichNovartisCompletedPyoderma GangrenosumGermany
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisThailand
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisUnited States
-
University of Erlangen-Nürnberg Medical SchoolActive, not recruiting
-
Novartis PharmaceuticalsCompletedStudy of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.Psoriatic ArthritisChina
-
Novartis PharmaceuticalsRecruitingModerate-to-severe Plaque PsoriasisRussian Federation